Evaluation of Sustained Minimal Residual Disease Negativity With Daratumumab-Combination Regimens in Relapsed and/or Refractory Multiple Myeloma: Analysis of POLLUX and CASTOR.
Herve Avet-LoiseauJesús San F MiguelTineke CasneufShinsuke IidaSagar LonialSaad Z UsmaniAndrew SpencerPhilippe MoreauTorben PlesnerKatja WeiselJon UkropecChristopher ChiuSonali TrivediHimal AminMaria KrevvataPriya RamaswamiXiang QinMia QiSteven SunMing QiRachel KobosNizar J BahlisPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021)
Daratumumab-based combinations induce higher rates of sustained MRD negativity versus standard of care, which are associated with durable remissions and prolonged clinical outcomes.